On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Novo Nordisk Foundation & Denmark invest €80M in a Microsoft-powered quantum computer to boost Nordic tech innovation.

The Danish government and the foundation behind Novo Nordisk A/S will invest €80 million ($93 million) in a Microsoft-powered ...

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...

Key Points Hims & Hers Health is entering the Canadian market.The company will offer a generic version of semaglutide in the ...

Clever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a global pharma ...

Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk has completed a 40-week clinical study titled ‘A ...

Novo Nordisk (NVO) closed the most recent trading day at $65.29, moving 2.61% from the previous trading session.

In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local ...

Novo Nordisk, a leading global healthcare company, is excited to announce a new Memorandum of Understanding with the Saudi ...